# Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma

> **NCT06323369** · PHASE2 · RECRUITING · sponsor: **Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University** · enrollment: 154 (estimated)

## Conditions studied

- Head and Neck Squamous Cell Carcinoma

## Interventions

- **DRUG:** Tislelizumab（neoadjuvant）
- **DRUG:** Cisplatin （neoadjuvant）
- **DRUG:** Nab-paclitaxel （neoadjuvant）
- **PROCEDURE:** Surgical resection
- **DRUG:** Cisplatin（adjuvant）
- **DRUG:** Tislelizumab（adjuvant）
- **RADIATION:** Radiation
- **DRUG:** Carboplatin（neoadjuvant）
- **DRUG:** Carboplatin（adjuvant）

## Key facts

- **NCT ID:** NCT06323369
- **Lead sponsor:** Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-25
- **Primary completion:** 2029-03-25
- **Final completion:** 2029-09-25
- **Target enrollment:** 154 (ESTIMATED)
- **Last updated:** 2024-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06323369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06323369, "Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06323369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*